ProSomnus Reports Successful Pilot Study Validation of Next Generation Remote Patient Monitoring Device for Obstructive Sleep Apnea

February 22, 2024

https://www.globenewswire.com/news-release/2024/02/22/2833687/0/en/ProSomnus-Reports-Successful-Pilot-Study-Validation-of-Next-Generation-Remote-Patient-Monitoring-Device-for-Obstructive-Sleep-Apnea.html

PLEASANTON, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) — ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea (OSA) therapy™, announced results of its pilot study for the Company’s Next Generation Remote Patient Monitoring (RPM) device for Obstructive Sleep Apnea (OSA). Data from the pilot study demonstrated that an oximeter embedded in a precision medical device can accurately, safely, and continuously monitor SpO2.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.